二甲双胍
医学
安慰剂
2型糖尿病
药品
临床试验
不利影响
人口
糖尿病
内科学
生物信息学
重症监护医学
老年学
药理学
内分泌学
替代医学
生物
病理
环境卫生
作者
Hartmut Glossmann,O. Lutz
出处
期刊:Gerontology
[S. Karger AG]
日期:2019-01-01
卷期号:65 (6): 581-590
被引量:136
摘要
Metformin is sometimes proposed to be an "anti-aging" drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type 2 diabetics. Large prospective, placebo-controlled trials are planned, in pilot stage or running, to find a new use (or indication) for an aging population. As one of the metformin trials has "frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.
科研通智能强力驱动
Strongly Powered by AbleSci AI